Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ABT-493/ABT-530 in adult transplant recipients with chronic hepatitis C completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, HCV | Phase 3 | Status: COMPLETED | Results posted: 2018-04-04